Our study highlights A-SMase as a target in AD to prevent microglia and astrocytes activation, and warrants synthesis and testing of brain permeable compounds, which specifically inhibit A-SMase as anti-AD therapeutic strategy. The gene discussed is SMPD1; the disease is Alzheimer disease.